


ASH DATA REVIEW 2024

February 20, 2025



AUGMENT 101: Revumenib is the first approved menin inhibitor and first approved treatment for KMT2Ar acute leukemia and should be considered for patients with KMT2Ar R/R acute leukemias

ASC4FRIST: Asciminib should be considered a standard of care treatment option for patients with newly diagnosed PH+ CML in chronic phase

QuANTUM-First: Quizartinib provides more clinical benefit versus placebo in patients <60 years of age and irrespective of baseline mutations for newly diagnosed FLT3-ITD-positive AML

SAVE: An all-oral combination of revumenib with decitabine/cedazuridine and venetoclax may provide additional benefit for patients with R/R AML

SENTRY: The combination of selinexor and ruxolitinib shows encouraging efficacy in ruxolitinib treated patients with myelofibrosis

EPO-Pretar: Early introduction of ESA in lower-risk MDS patients with anemia did not delay time to RBC transfusion dependence

AQUILA: Early intervention with daratumumab monotherapy in patients with high-risk smoldering multiple myeloma may delay or prevent progression to active multiple myeloma

IFM2017-03: Daratumumab plus lenalidomide (with dexamethasone-sparing) is an effective and safe treatment for frail patients with newly diagnosed MM

MajesTEC-4: Tectamab maintenance, alone or in combination with lenalidomide, is an effective strategy for patients with newly diagnosed multiple myeloma following ASCT

MajesTEC-5: Tectamab in combination with daratumumab-based standard of care could benefit transplant eligible patients with newly diagnosed multiple myeloma
Given risk of AEs may only be an option at academic centers...

DREAMM-7: Belantamab mafodotin plus bortezomib and dexamethasone could be considered a new standard of care for patients with R/R MM after more than one line of therapy, but ocular toxicity remains a concern.
A Prescription Drug User Fee Act (PDUFA) target action date has been set for July 23, 2025

IMROZ: Transplant ineligible newly diagnosed MM patients had improved PFS and better response with ISA-VRd (initiation therapy) followed by Isa-RD (maintenance therapy) and should be considered a standard of care

inMIND: Tafasitamab in combination with lenalidomide and rituximab is a potential new treatment option for patients with R/R follicular lymphoma
inMIND supports combining anti-CD19 and anti-CD20 agents for FL but... Not yet approved...

ECOG-ACRIN EA4151: MCL patients in first complete remission with undetectable minimal residual disease (MRD) may safely avoid consolidative ASCT
Longer follow-up needed...

TRIANGLE: Rituximab maintenance prolongs PFS and should be considered standard of care
Ibrutinib containing regimens may be the preferred 1L treatment for younger patients and most can safely avoid ASCT

ENRICH: Benefit of ibrutinib in combination with rituximab versus immunochemotherapy for patients with previously untreated MCL
But... primarily driven by benefit over R-CHOP; similar efficacy versus BR

BRUIN CLL-321: For heavily pretreated patients, pirtobrutinib provides benefit compared to standard therapies and should be considered for patients with later stage CLL/SL

waveLINE-007: Zilovetamab vedotin in combination with R-CHP shows promising efficacy in patients with untreated DLBCL... more to come...

Program Chairs

PANKIT VACHHANI, MD
Associate Professor of Medicine
University of Alabama at Birmingham, AL
Leukemia

ERIC S. SCHAEFER, MD
Medical Oncologist
Highlands Oncology Group, Fayetteville, AR
Myeloma

SUJITH R. KALMADI, MD
Medical Oncologist, Chief Medical Officer
Ironwood Cancer and Research Centers, Phoenix, AZ
Lymphoma

cornerstone
specialty network™

© 2025 Cornerstone Specialty Network, LLC.
All rights reserved.
P.O. Box 173 - New Hope, PA 18938
v022025